KYINNO Antibody Production Platform: Your Partner in High-Quality Antibody Development

Antibody Production Overview

At the KYINNO Antibody Production Platform, we are committed to the development and production of high-quality antibodies for early drug discovery and preclinical research. Leveraging our optimized mammalian cell expression system, we offer comprehensive antibody expression and production services based on HEK293/CHO cells. Beginning with antibody sequence information, we provide customers with a one-stop solution encompassing gene construction, expression, purification, quality testing, and delivery of antibodies with high purity and low endotoxin levels.

Our antibody expression utilizes a mammalian cell expression system, employing both transient small-scale expression and stable transfection to establish large-scale expression cell lines. The transient transfection system includes Expi-CHOS, Expi-293F, and the corresponding FUT8 knockout system, which effectively enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Additionally, the stable transfection cell line expression system employs CHOK1 cells in conjunction with the GS knockout system and GS-FUT8 double knockout system. These expression systems are carefully chosen to ensure optimal product quality and yield.

Our antibody production platform is equipped with comprehensive hardware, including bioreactors, five AKTA systems, and a range of quality testing instruments such as Fortebio, flow cytometers, HPLC, CE/SDS, and LC/MS.

We offer a comprehensive array of services, from antibody production to quality testing. Furthermore, the buffer stored in the product can be customized to meet specific formulation requirements.

The KYINNO Antibody Production Platform provides an all-encompassing service, starting with gene construction and expression based on antibody sequence information. Our efficient and rapid recombinant antibody expression services involve the transfer of CHO/HEK293 cells, enabling the delivery of purified antibodies in as little as 2 weeks, all while meeting high yield and concentration specifications tailored to your downstream applications.

We offer a comprehensive array of services, from antibody production to quality testing. Furthermore, the buffer stored in the product can be customized to meet specific formulation requirements.

The KYINNO Antibody Production Platform provides an all-encompassing service, starting with gene construction and expression based on antibody sequence information. Our efficient and rapid recombinant antibody expression services involve the transfer of CHO/HEK293 cells, enabling the delivery of purified antibodies in as little as 2 weeks, all while meeting high yield and concentration specifications tailored to your downstream applications.

With a stringent quality control system in place, KYINNO has amassed extensive successful experience in large-scale antibody production. Our products undergo rigorous testing, including molecular weight analysis, purity assessment, stability analysis, affinity and bioactivity verification, as well as functional and in vivo assays. We possess the capability to optimize culture and production programs to fulfill large-scale production demands, offering antibody production ranging from milligrams to grams, all compliant with the <0.5EU/mg endotoxin standard.

Our current inventory boasts a wide selection of 100 Benchmark antibodies, encompassing over 20 human IgG isotypes with Fc modifications, along with control antibodies targeting various antigens. Rest assured, each of these antibodies has undergone thorough quality control checks.

In addition to our standard services, we offer specialized assistance in constructing antibody expression stable transfection cell lines. This process involves gene synthesis, cell transfection, monoclonal screening, rigorous quality assessment, and the ultimate delivery of qualified antibody expression stable transfection cell lines.

Remarkably, the KYINNO Antibody Production Platform has successfully constructed stable transfection cell lines for over 20 antibodies.

All Antibody Discovery Services

Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.

Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.

Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.

Taking advantage of camelid-derived nanobodies, we present a distinct antibody structure providing exceptional therapeutic versatility. This innovation leads to innovative approaches to treatments and diagnostics and broadens the modern medical solutions.
In silico developability assessment, transforming biomedicine by providing groundbreaking approaches to predicting antibody developability. Leveraging advanced computational insights, streamline research processes, enhance therapeutic product robustness, and accelerate innovative drug discovery.
With our profound expertise, we optimize antibodies for human compatibility, boosting therapeutic outcomes. Reducing adverse reactions, we lay the groundwork for innovative, patient-focused personalized medicine, customized for each individual.
Our comprehensive assessment of drug potential and immune responses guarantees therapeutic safety and efficacy. This rigorous process is vital in bridging the transition from lab research to successful clinical stage implementation.
Using antibodies with high specificity, we guarantee precise binding targets for CAR-T cells and biologics. This meticulous approach is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.
Targeting G-protein coupled receptors, we access an expansive therapeutic domain. Concentrating on these essential proteins, we not only enhance drug efficacy but also pioneer breakthroughs, broadening horizons in modern drug development.
Nanobodies, featuring high affinity and stability, revolutionize therapeutic approaches. Their unique properties make them invaluable, especially in the areas of targeted drug delivery, advanced diagnostics, and innovative disease intervention strategies.
KYINNO sets the standard, prioritizing high-quality antibody production. We emphasize unmatched consistency, purity, and reliability, setting industry guidelines, fostering trust, and accelerating groundbreaking drug discovery and innovative research endeavors.
Bispecific antibodies from KY-CLC bind two distinct antigens, offering advanced therapeutic avenues, enhancing drug delivery, and increasing the potential for successful patient outcomes.
Nanobodies, known for their small molecular weight, high affinity, stability, permeability, and cost-effectiveness, have demonstrated tremendous potential in disease …